Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity.
Animal research · 2022
- What was studied
- Rats; intravenous and intragastric pharmacokinetics
- Main finding
- GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.
Study data at a glance
- Participants or experimental model
- Rats; intravenous and intragastric pharmacokinetics
- Reported results
- GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.
Study limitations and source details
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Source details
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Abstract reviewed
Sources checked
Citation
Litvin AA, Kolyvanov GB, Bochkov PO, Shevchenko RV, Podol'ko AL, Kolyasnikova KN, Zherdev VP. Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity. Bulletin of experimental biology and medicine
Study source ↗ · DOI 10.1007/s10517-022-05400-x · Bibliography entry · Link to this summary